Gandhi Maher K, Tellam Judy T, Khanna Rajiv
Department of Tumour Immunology, Division of Infectious Diseases and Immunology, Queensland Institute of Medical Research, Herston, Brisbane, Queensland, Australia.
Br J Haematol. 2004 May;125(3):267-81. doi: 10.1111/j.1365-2141.2004.04902.x.
Survivors of Hodgkin's lymphoma (HL) frequently have many years to experience the long-term toxicities of combined modality therapies. Also, a significant proportion of HL patients will relapse or have refractory disease, and less than half of these patients will respond to current salvage strategies. 30-50% of HL cases are Epstein-Barr virus associated (EBV-positive HL). The virus is localized to the malignant cells and is clonal. EBV-positive HL is more frequent in childhood, in older adults (>45 years) and in mixed cellularity cases. The survival of EBV-positive HL in the elderly and the immunosuppressed is particularly poor. Despite improvements in our understanding of EBV-positive HL, the true contribution of EBV to the pathogenesis of HL remains unknown. Increased knowledge of the virus' role in the basic biology of HL may generate novel therapeutic strategies for EBV-positive HL and the presence of EBV-latent antigens in the malignant HL cells may represent a target for cellular immunotherapy.
霍奇金淋巴瘤（HL）幸存者常常需要多年时间来承受综合治疗带来的长期毒性。此外，相当一部分HL患者会复发或患有难治性疾病，而这些患者中不到一半会对当前的挽救策略产生反应。30%至50%的HL病例与爱泼斯坦-巴尔病毒相关（EBV阳性HL）。该病毒定位于恶性细胞且呈克隆性。EBV阳性HL在儿童、老年人（>45岁）以及混合细胞型病例中更为常见。老年和免疫抑制患者中EBV阳性HL的生存率尤其低。尽管我们对EBV阳性HL的认识有所提高，但EBV在HL发病机制中的真正作用仍不清楚。对该病毒在HL基础生物学中作用的更多了解可能会为EBV阳性HL带来新的治疗策略，并且恶性HL细胞中EBV潜伏抗原的存在可能成为细胞免疫治疗的靶点。
